MORGAN STANLEY PLC/CALL/BRISTOL-MYERS SQUIBB/56/0.1/20.09.24 | Market Closed - Börse Stuttgart 12:59:53 2024-07-12 pm EDT | ||
| 0.024 EUR | 0.00% |
|
| 1 month | +26.32% | ||
| 3 months | -76.70% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 0.024 | 0.00% |
| 24-07-11 | 0.024 | -4.00% |
| 24-07-10 | 0.025 | 0.00% |
| 24-07-09 | 0.025 | 0.00% |
| 24-07-08 | 0.025 | +4.17% |
Delayed Quote Börse Stuttgart
Last update July 12, 2024 at 12:59 pm EDT
More quotesStatic data
| Product type | Warrant Plain-Vanilla |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | Morgan Stanley |
| WKN | ME48AX |
| ISIN | DE000ME48AX3 |
| Date issued | 2023-11-28 |
| Strike | 56 $ |
| Maturity | 2024-09-20 (70 Days) |
| Parity | 10 : 1 |
| Emission price | 0.27 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.31 € |
|---|---|
| Lowest since issue | 0.013 € |
| Spread | 0.016 € |
| Spread % | 40.00% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
40.46
USD
Average target price
52.74
USD
Spread / Average Target
+30.35%
- Stock Market
- Warrants
- Warrant
